China defines norms for breast cancer treatment

China has decided to promote a package for breast cancer prevention and treatment standards across the country, hoping to prolong patients' survival and narrow the diagnosis and treatment gap between urban and rural areas.

A series of guidelines, covering breast cancer screening, early diagnosis and treatment and rational drug use to follow-up treatment and management of concomitant diseases, were released on Saturday at a conference, jointly organised by the National Cancer Center (NCC), the Cancer Foundation of China, the Beijing Breast Disease Society and others, the Xinhua news agency reported.

The NCC data, released in March 2018, showed the breast cancer mortality in China accounted for 16.5 per cent of all cancers in women. However, the cure rate has been improving steadily with the five-year survival rate reaching 83.2 per cent between 2010 and 2014, up 7.3 per cent since 2000.

As survival time has been stretched, more patients have entered a chronic disease period, according to the guidelines for breast cancer follow-up and overall management of concomitant diseases, the first of its kind in China, by the NCC.

Common concomitant diseases of breast cancer, include cardiovascular diseases, abnormal bone metabolism and depression. "Among elder patients, cardiovascular diseases have caused even more deaths than cancer," said Ma Fei, Executive Chairman of the conference and NCC expert.

Under the dual effects of ovarian dysfunction and drugs, postmenopausal patients suffer a distinct drop in estrogen levels, which often causes an abnormal lipid amount in the blood and increases the risk of cardiovascular diseases, Ma said.

In addition, a large number of patients will continue to receive endocrine therapy for 5-10 years after cancer treatment, which is often accompanied by abnormal bone metabolism, osteoporosis and fractures.

The guidelines require doctors, through inter-disciplinary collaborations, to take into consideration a patient's blood lipid level and bone density before advising endocrine therapy. It also suggests doctors should intervene to help patients quit smoking and alcohol as well as avoid falls and serious body impacts.

According to Ma Fei, the guidelines is an important step to change the disease-centred diagnosis and treatment model into a patient-centred one. "The patients should not only live longer, but also live well," he said.

China issued the blueprint for health care development "Healthy China 2030" in 2016, aiming to raise the 5-year cancer survival rate by 15 percentage points by 2030.

As for breast cancer, the five-year survival rate varies in different areas. The eastern coastal cities report a survival rate of 90 per cent, roughly the same level as in developed Western countries, while the inland and rural area rates are lower at 70-80 per cent.

Moreover, the incidence of breast cancer in China is still growing 3-4 per cent a year, which is higher than the global average.

"To improve the breast cancer cure rate, early diagnosis and treatment are important. At present, not more than 20 per cent breast cancer cases are detected at an early stage, and less than 5 per cent are found by screening," Ma said.